MRC1 and neoplasm: By quantitative immunohistochemistry we found that cisplatin-based NACT has not resulted in the biologically significant decrease of total amount of CD68+ TAMs and amount of CD206+ and stabilin-1+ M2-like TAMs in the remaining tumor tissue compared to the non-treated tumor.